David C. Crosby is a medical science liaison with over 15 years of experience in infectious disease research and medical communications. He has worked at several biotech companies, including his current role at Melinta Therapeutics where he engages with key opinion leaders to discuss Melinta's antibiotic pipeline. Crosby also has a background in virology research, having conducted HIV/AIDS studies at the University of California, San Francisco and the University of California, Irvine where he received his Ph.D. He is experienced in scientific engagement, competitive intelligence gathering, and distilling medical information for commercial and clinical functions.
Identification of poisoning-EM ANDHRA2021Befin Kezhson
1. The history of toxicology began around 1225 AD when poisons were first described as potions made with deadly ingredients. Early poisons consisted mainly of plant extracts, animal venoms, and minerals used for hunting and executions.
2. Toxicology developed as a medical field after World War II, with the first poison control centers appearing in the 1940s. Toxicology deals with detecting and treating poisoning and the "father of modern toxicology" is considered Mathieu Joseph Bonaventure Orfila from the early 19th century.
3. Poisonings can be deliberate (intentional) through suicide or homicide, or accidental from misdosing, environmental exposures, or industrial accidents. In
A 30-year-old man presented with a right testicular mass and bilateral gynecomastia. Radical right orchiectomy showed a Leydig cell tumor on histopathology.
A 55-year-old man with resting tremors, rigidity, and bradykinesia was diagnosed with Parkinson's disease. After 2 months on Levodopa therapy with no improvement, the most likely diagnosis is multiple system atrophy. Neuropathological examination would show alpha-synuclein and ubiquitin deposits.
A 9-month-old boy with poor weight gain, bulky stools, and Bitot spots was found to have a mutation in the microsomal triglycer
This document contains multiple patient case summaries and medical images/reports with questions related to diagnosis and management. Some key cases include:
- A 55-year-old male presenting with shortness of breath, whose chest X-ray shows cardiomegaly and upper lobe diversion.
- A 35-year-old male with progressive shortness of breath and cough presenting with bilateral hilar lymphadenopathy on chest X-ray, leading to a diagnosis of sarcoidosis.
- An ECG showing findings of atrial fibrillation in a 35-year-old female presenting with palpitations.
- A CT scan of a 30-year-old IV drug user presenting with fever
Osteomalacia is a softening of the bones due to vitamin D deficiency which impairs bone mineralization. It commonly affects elderly individuals, those with a family history of rickets, people of black or South Asian descent, and patients with gastrointestinal, renal or tumor conditions that interfere with vitamin D absorption or metabolism. Symptoms include bone pain, muscle weakness, and increased risk of fractures. Diagnosis involves blood tests to measure calcium, phosphate, vitamin D, and alkaline phosphatase levels. Treatment focuses on increasing vitamin D through sun exposure, dietary sources, and supplementation.
Anatomy Question Bank for the NExT / NEET-PG 2023 ExamShivankan Kakkar
The document discusses the lymph nodes removed during surgery for a melanoma on the left forearm. It states that all axillary lymph nodes lateral to the medial edge of the pectoralis minor muscle would be removed. However, the apical lymph nodes, which are located medial to the medial edge of pectoralis minor, would not be removed.
This document provides a historical perspective on thyroid gland and thyroid surgery. Some key points covered include:
- Goiter was first documented in the Alps and consuming seaweed was found to cure it due to its high iodine content.
- Leonardo da Vinci discovered and drew detailed sketches of the thyroid gland in the early 1500s.
- In the late 1500s/early 1600s, links were established between goiter in mothers and cretinism in children.
- Iodine was discovered as the key nutrient in preventing goiter in the early 1800s.
- The first total thyroidectomy was performed in 1867 and Theodor Kocher performed over 100 thyroid surgeries,
Hiperventilasi adalah keadaan pernafasan terlalu cepat yang menyebabkan penurunan karbon dioksida dalam darah. Gejala hiperventilasi disebabkan oleh berbagai faktor seperti kecemasan, kesakitan, obat-obatan, dan penyakit. Diagnosa ditegakkan dengan uji provokasi dan rawatannya meliputi penjelasan, relaksasi, serta bernafas di dalam beg kertas.
This document provides an overview of Good Clinical Practice (GCP) and the International Conference on Harmonisation (ICH). It discusses key events that led to the development of ethical standards in clinical research. The ICH was formed to harmonize technical requirements for drug approval among regions. It establishes guidelines covering non-clinical studies, clinical safety, efficacy, quality, and multidisciplinary topics. The core purpose of GCP and ICH guidelines is to protect research participants and ensure valid clinical trial conduct and data.
Identification of poisoning-EM ANDHRA2021Befin Kezhson
1. The history of toxicology began around 1225 AD when poisons were first described as potions made with deadly ingredients. Early poisons consisted mainly of plant extracts, animal venoms, and minerals used for hunting and executions.
2. Toxicology developed as a medical field after World War II, with the first poison control centers appearing in the 1940s. Toxicology deals with detecting and treating poisoning and the "father of modern toxicology" is considered Mathieu Joseph Bonaventure Orfila from the early 19th century.
3. Poisonings can be deliberate (intentional) through suicide or homicide, or accidental from misdosing, environmental exposures, or industrial accidents. In
A 30-year-old man presented with a right testicular mass and bilateral gynecomastia. Radical right orchiectomy showed a Leydig cell tumor on histopathology.
A 55-year-old man with resting tremors, rigidity, and bradykinesia was diagnosed with Parkinson's disease. After 2 months on Levodopa therapy with no improvement, the most likely diagnosis is multiple system atrophy. Neuropathological examination would show alpha-synuclein and ubiquitin deposits.
A 9-month-old boy with poor weight gain, bulky stools, and Bitot spots was found to have a mutation in the microsomal triglycer
This document contains multiple patient case summaries and medical images/reports with questions related to diagnosis and management. Some key cases include:
- A 55-year-old male presenting with shortness of breath, whose chest X-ray shows cardiomegaly and upper lobe diversion.
- A 35-year-old male with progressive shortness of breath and cough presenting with bilateral hilar lymphadenopathy on chest X-ray, leading to a diagnosis of sarcoidosis.
- An ECG showing findings of atrial fibrillation in a 35-year-old female presenting with palpitations.
- A CT scan of a 30-year-old IV drug user presenting with fever
Osteomalacia is a softening of the bones due to vitamin D deficiency which impairs bone mineralization. It commonly affects elderly individuals, those with a family history of rickets, people of black or South Asian descent, and patients with gastrointestinal, renal or tumor conditions that interfere with vitamin D absorption or metabolism. Symptoms include bone pain, muscle weakness, and increased risk of fractures. Diagnosis involves blood tests to measure calcium, phosphate, vitamin D, and alkaline phosphatase levels. Treatment focuses on increasing vitamin D through sun exposure, dietary sources, and supplementation.
Anatomy Question Bank for the NExT / NEET-PG 2023 ExamShivankan Kakkar
The document discusses the lymph nodes removed during surgery for a melanoma on the left forearm. It states that all axillary lymph nodes lateral to the medial edge of the pectoralis minor muscle would be removed. However, the apical lymph nodes, which are located medial to the medial edge of pectoralis minor, would not be removed.
This document provides a historical perspective on thyroid gland and thyroid surgery. Some key points covered include:
- Goiter was first documented in the Alps and consuming seaweed was found to cure it due to its high iodine content.
- Leonardo da Vinci discovered and drew detailed sketches of the thyroid gland in the early 1500s.
- In the late 1500s/early 1600s, links were established between goiter in mothers and cretinism in children.
- Iodine was discovered as the key nutrient in preventing goiter in the early 1800s.
- The first total thyroidectomy was performed in 1867 and Theodor Kocher performed over 100 thyroid surgeries,
Hiperventilasi adalah keadaan pernafasan terlalu cepat yang menyebabkan penurunan karbon dioksida dalam darah. Gejala hiperventilasi disebabkan oleh berbagai faktor seperti kecemasan, kesakitan, obat-obatan, dan penyakit. Diagnosa ditegakkan dengan uji provokasi dan rawatannya meliputi penjelasan, relaksasi, serta bernafas di dalam beg kertas.
This document provides an overview of Good Clinical Practice (GCP) and the International Conference on Harmonisation (ICH). It discusses key events that led to the development of ethical standards in clinical research. The ICH was formed to harmonize technical requirements for drug approval among regions. It establishes guidelines covering non-clinical studies, clinical safety, efficacy, quality, and multidisciplinary topics. The core purpose of GCP and ICH guidelines is to protect research participants and ensure valid clinical trial conduct and data.
This study evaluated the efficacy and safety of lacosamide in treating diabetic neuropathic pain through an 18-week double-blind trial of 370 patients with doses of 200 mg/day, 400 mg/day, and 600 mg/day compared to a placebo. The 400 mg/day dose was found to significantly improve pain scores over the placebo and had the optimal balance of efficacy and side effects. Common side effects included dizziness, tremor and headache. While lacosamide showed potential for treating diabetic neuropathic pain, the study period was short and the 600 mg/day group had a high withdrawal rate due to adverse events.
This document discusses uncontrolled clinical trials, which evaluate new medical treatments without a control group for comparison. Uncontrolled trials have limitations since they lack a control group, but they can provide preliminary insights into treatment safety and efficacy. They help generate hypotheses for further research and justify larger controlled trials. The document provides examples of uncontrolled trials in various phases of clinical research. While uncontrolled trials are not as rigorous as controlled trials, they still play an important role in the early evaluation of novel medical therapies.
The document discusses liver disorders and provides information on various cases, including:
- A 51-year-old alcoholic man whose liver specimen showed cirrhosis.
- Test results from a 42-year-old man undergoing insurance screening suggested post-viral cirrhosis as the most likely diagnosis.
- A 69-year-old woman who died of cardiac failure was found to have cirrhosis on liver examination.
The document provides a summary of the qualifications and experience of David C. Crosby, Ph.D. It includes his contact information and outlines his experience in medical science liaison roles in infectious disease, as well as his background in virology research. It also lists his education, publications, presentations, and professional affiliations.
Bryan Soper has extensive experience in pharmaceutical competitive intelligence, medical writing, and data analysis. He currently performs contract work analyzing clinical trials and assessing drug approval likelihoods for Genentech. Previously he has analyzed cancer models and clinical trials to identify correlations. He holds a PhD in Molecular Biology from Cornell University and has worked as a postdoctoral scholar at UCSF investigating drug targets.
Homa Assar has over 15 years of experience as a technical writer and editor for the National Cancer Institute and NIH. She has expertise in writing for clinical trials, FDA regulations, and informed consent forms. Her experience also includes maintaining databases, translating medical documents, and authoring scientific publications. She is highly skilled in English, Persian, French, Italian, and German.
This document provides a summary of the qualifications and experience of Francesca Madiai, PhD. She has over 10 years of experience as a clinical research coordinator, with expertise in areas such as project planning, data collection, protocol development, and GCP compliance. Her background includes a PhD in Molecular, Cellular and Developmental Biology from Ohio State University and over 10 publications in scientific journals. She has coordinated over 50 clinical trials in rheumatology and has experience with regulatory submissions, study execution, and patient recruitment.
Robert V. Brown is a Ph.D. in Pharmaceutical Sciences with expertise in ocular molecular biology, drug discovery, and development. He has over 10 years of experience in academic research and currently works as a postdoctoral research fellow at the National Institute of Environmental Health Sciences. His background includes developing disease models, managing multi-institute research projects, and publishing papers on targeting non-B DNA structures for transcription regulation.
Alex Michael Ward is a virologist and cell biologist seeking a research position in biotech. He has 14 years of experience studying virus-host interactions and identifying therapeutic targets using genetic, proteomic, and cell-based approaches. He is a highly collaborative scientist who has independently managed a research team and obtained external funding. His work has resulted in numerous publications, presentations, and the development of novel assays.
Katrina Welch-Reardon has extensive scientific research experience and seeks a business role in a scientific organization. She has a Ph.D. in Biological Sciences from UC Irvine and certificates in bioscience management. Her career includes roles managing admissions events, scientific writing and project management, and graduate research investigating angiogenesis. She has strong communication, organizational and leadership skills as shown through successful event planning, publishing papers, and managing teams of researchers.
Jennifer Anne Gibbons has over 15 years of experience in research biology and scientific support roles related to chemical and biological defense. She currently works as a Research Biologist at the US Army Edgewood Chemical Biological Center, where she performs research on physiological and biochemical changes resulting from exposure to chemical threat agents. Previously she held roles at Excet, Inc. and the Science and Technology Corporation, supporting research at Edgewood CBC. Gibbons has a Ph.D. in Pharmacology from Duke University and develops assays and detection methods for threats such as nerve agents and tick-borne pathogens. She has authored several publications and technical reports on topics including biomarker detection of chemical exposure and evaluation of detection assays.
Romain Banchereau is a computational biologist and translational immunologist focused on analyzing immune cell populations and transcriptional profiles from human disease cohorts. He has expertise in genomics analysis of blood and immune cells from infectious and autoimmune disease patients. Through bioinformatics analysis, he identifies biomarkers for disease diagnosis, prognosis, and response to treatment. He currently works as a research associate applying these skills to study lupus, juvenile arthritis, and complications during pregnancy with SLE.
Philippa Strong has over 15 years of experience in molecular microbiology in both academia and industry. She has significant expertise in culturing anaerobic bacteria, genetic manipulation, protein purification, and fluorescence microscopy. Her technical skills include protein expression and purification, live cell imaging, PCR, cloning, and bacterial isolation from human samples. She has worked on projects involving C. difficile, acetogenic bacteria, and Campylobacter jejuni. Her roles have included postdoctoral research, developing novel biotherapeutics, and optimizing growth of acetogenic bacteria for chemical production. She has authored several peer-reviewed publications and presented her work at international conferences.
This document provides a summary of Alexander Polinkovsky's professional experience and education. It lists his positions from 2014 to present as a clinical and biomedical research consultant. It also outlines his previous roles as a research lab manager and researcher from 2011 to 2014 at the Louis Stokes V.A. Medical Center and from 2009 to 2011 at Case Western Reserve University. It notes that he has a Ph.D. in Biology and Virology from 1981 and has experience in areas like microbiome studies, DNA/RNA extraction, metabolomics, and proteomics.
Lindsay Jordan has over 15 years of experience in the pharmaceutical industry, specializing in immunology techniques including cell culture, molecular biology, and ELISA development. She has worked at Biothera Pharmaceuticals since 2007 where she developed and validated potency assays, authored SOPs, and supported clinical trials. Prior to this, she held positions at 3M Pharmaceuticals and ViroMED Laboratories, optimizing assays and discovering drug mechanisms of action. Jordan has a Bachelor's degree in Biology and is proficient in laboratory techniques and data analysis software. She has authored multiple publications and presentations on topics including beta-glucan immunology and cancer immunotherapy.
This document provides a summary of Tibor Farkas's qualifications and experience. He has over 20 years of experience in microbiology and virology research, particularly regarding enteric viruses, at Cincinnati Children's Hospital and previously in Hungary. His research accomplishments include the discovery and characterization of several novel viral pathogens. He has strong skills in laboratory techniques, experimental design, and leadership.
This document provides a summary of Y. Nancy Wong's experience and qualifications. She has over 30 years of experience in drug metabolism and pharmacokinetics (DMPK) supporting drug discovery and development. She has expertise in bioanalytical method development, drug discovery, drug development, clinical development, and managerial experience. She has worked at several pharmaceutical companies in roles of increasing responsibility, and currently works as a consultant.
This document provides a summary of Ana Gervassi's qualifications and experience. She has over 20 years of experience in immunology, infectious diseases, vaccine research, and program management. She is currently the Cellular Immunology Subcore Director at the Center for AIDS Research and a Senior Scientist at the Center for Infectious Disease Research, where she manages a research laboratory.
Jason C. Poole has 17 years of experience as a molecular biologist developing novel molecular and genetic assays. He has a PhD in molecular genetics and most recently worked at EMD Millipore developing qPCR and next generation sequencing assays that were commercialized. He is seeking a senior scientist or project leader position and has strong skills in areas like qPCR, sequencing, cloning, and assay development.
This study evaluated the efficacy and safety of lacosamide in treating diabetic neuropathic pain through an 18-week double-blind trial of 370 patients with doses of 200 mg/day, 400 mg/day, and 600 mg/day compared to a placebo. The 400 mg/day dose was found to significantly improve pain scores over the placebo and had the optimal balance of efficacy and side effects. Common side effects included dizziness, tremor and headache. While lacosamide showed potential for treating diabetic neuropathic pain, the study period was short and the 600 mg/day group had a high withdrawal rate due to adverse events.
This document discusses uncontrolled clinical trials, which evaluate new medical treatments without a control group for comparison. Uncontrolled trials have limitations since they lack a control group, but they can provide preliminary insights into treatment safety and efficacy. They help generate hypotheses for further research and justify larger controlled trials. The document provides examples of uncontrolled trials in various phases of clinical research. While uncontrolled trials are not as rigorous as controlled trials, they still play an important role in the early evaluation of novel medical therapies.
The document discusses liver disorders and provides information on various cases, including:
- A 51-year-old alcoholic man whose liver specimen showed cirrhosis.
- Test results from a 42-year-old man undergoing insurance screening suggested post-viral cirrhosis as the most likely diagnosis.
- A 69-year-old woman who died of cardiac failure was found to have cirrhosis on liver examination.
The document provides a summary of the qualifications and experience of David C. Crosby, Ph.D. It includes his contact information and outlines his experience in medical science liaison roles in infectious disease, as well as his background in virology research. It also lists his education, publications, presentations, and professional affiliations.
Bryan Soper has extensive experience in pharmaceutical competitive intelligence, medical writing, and data analysis. He currently performs contract work analyzing clinical trials and assessing drug approval likelihoods for Genentech. Previously he has analyzed cancer models and clinical trials to identify correlations. He holds a PhD in Molecular Biology from Cornell University and has worked as a postdoctoral scholar at UCSF investigating drug targets.
Homa Assar has over 15 years of experience as a technical writer and editor for the National Cancer Institute and NIH. She has expertise in writing for clinical trials, FDA regulations, and informed consent forms. Her experience also includes maintaining databases, translating medical documents, and authoring scientific publications. She is highly skilled in English, Persian, French, Italian, and German.
This document provides a summary of the qualifications and experience of Francesca Madiai, PhD. She has over 10 years of experience as a clinical research coordinator, with expertise in areas such as project planning, data collection, protocol development, and GCP compliance. Her background includes a PhD in Molecular, Cellular and Developmental Biology from Ohio State University and over 10 publications in scientific journals. She has coordinated over 50 clinical trials in rheumatology and has experience with regulatory submissions, study execution, and patient recruitment.
Robert V. Brown is a Ph.D. in Pharmaceutical Sciences with expertise in ocular molecular biology, drug discovery, and development. He has over 10 years of experience in academic research and currently works as a postdoctoral research fellow at the National Institute of Environmental Health Sciences. His background includes developing disease models, managing multi-institute research projects, and publishing papers on targeting non-B DNA structures for transcription regulation.
Alex Michael Ward is a virologist and cell biologist seeking a research position in biotech. He has 14 years of experience studying virus-host interactions and identifying therapeutic targets using genetic, proteomic, and cell-based approaches. He is a highly collaborative scientist who has independently managed a research team and obtained external funding. His work has resulted in numerous publications, presentations, and the development of novel assays.
Katrina Welch-Reardon has extensive scientific research experience and seeks a business role in a scientific organization. She has a Ph.D. in Biological Sciences from UC Irvine and certificates in bioscience management. Her career includes roles managing admissions events, scientific writing and project management, and graduate research investigating angiogenesis. She has strong communication, organizational and leadership skills as shown through successful event planning, publishing papers, and managing teams of researchers.
Jennifer Anne Gibbons has over 15 years of experience in research biology and scientific support roles related to chemical and biological defense. She currently works as a Research Biologist at the US Army Edgewood Chemical Biological Center, where she performs research on physiological and biochemical changes resulting from exposure to chemical threat agents. Previously she held roles at Excet, Inc. and the Science and Technology Corporation, supporting research at Edgewood CBC. Gibbons has a Ph.D. in Pharmacology from Duke University and develops assays and detection methods for threats such as nerve agents and tick-borne pathogens. She has authored several publications and technical reports on topics including biomarker detection of chemical exposure and evaluation of detection assays.
Romain Banchereau is a computational biologist and translational immunologist focused on analyzing immune cell populations and transcriptional profiles from human disease cohorts. He has expertise in genomics analysis of blood and immune cells from infectious and autoimmune disease patients. Through bioinformatics analysis, he identifies biomarkers for disease diagnosis, prognosis, and response to treatment. He currently works as a research associate applying these skills to study lupus, juvenile arthritis, and complications during pregnancy with SLE.
Philippa Strong has over 15 years of experience in molecular microbiology in both academia and industry. She has significant expertise in culturing anaerobic bacteria, genetic manipulation, protein purification, and fluorescence microscopy. Her technical skills include protein expression and purification, live cell imaging, PCR, cloning, and bacterial isolation from human samples. She has worked on projects involving C. difficile, acetogenic bacteria, and Campylobacter jejuni. Her roles have included postdoctoral research, developing novel biotherapeutics, and optimizing growth of acetogenic bacteria for chemical production. She has authored several peer-reviewed publications and presented her work at international conferences.
This document provides a summary of Alexander Polinkovsky's professional experience and education. It lists his positions from 2014 to present as a clinical and biomedical research consultant. It also outlines his previous roles as a research lab manager and researcher from 2011 to 2014 at the Louis Stokes V.A. Medical Center and from 2009 to 2011 at Case Western Reserve University. It notes that he has a Ph.D. in Biology and Virology from 1981 and has experience in areas like microbiome studies, DNA/RNA extraction, metabolomics, and proteomics.
Lindsay Jordan has over 15 years of experience in the pharmaceutical industry, specializing in immunology techniques including cell culture, molecular biology, and ELISA development. She has worked at Biothera Pharmaceuticals since 2007 where she developed and validated potency assays, authored SOPs, and supported clinical trials. Prior to this, she held positions at 3M Pharmaceuticals and ViroMED Laboratories, optimizing assays and discovering drug mechanisms of action. Jordan has a Bachelor's degree in Biology and is proficient in laboratory techniques and data analysis software. She has authored multiple publications and presentations on topics including beta-glucan immunology and cancer immunotherapy.
This document provides a summary of Tibor Farkas's qualifications and experience. He has over 20 years of experience in microbiology and virology research, particularly regarding enteric viruses, at Cincinnati Children's Hospital and previously in Hungary. His research accomplishments include the discovery and characterization of several novel viral pathogens. He has strong skills in laboratory techniques, experimental design, and leadership.
This document provides a summary of Y. Nancy Wong's experience and qualifications. She has over 30 years of experience in drug metabolism and pharmacokinetics (DMPK) supporting drug discovery and development. She has expertise in bioanalytical method development, drug discovery, drug development, clinical development, and managerial experience. She has worked at several pharmaceutical companies in roles of increasing responsibility, and currently works as a consultant.
This document provides a summary of Ana Gervassi's qualifications and experience. She has over 20 years of experience in immunology, infectious diseases, vaccine research, and program management. She is currently the Cellular Immunology Subcore Director at the Center for AIDS Research and a Senior Scientist at the Center for Infectious Disease Research, where she manages a research laboratory.
Jason C. Poole has 17 years of experience as a molecular biologist developing novel molecular and genetic assays. He has a PhD in molecular genetics and most recently worked at EMD Millipore developing qPCR and next generation sequencing assays that were commercialized. He is seeking a senior scientist or project leader position and has strong skills in areas like qPCR, sequencing, cloning, and assay development.
This document provides a summary of Jack Ryan Reifert's education, experience, publications, and research skills. Reifert holds a Ph.D. in Molecular, Cellular, and Developmental Biology from UCSB and a B.S. in Pharmacological Chemistry from UCSD. He has postdoctoral and research experience studying mechanisms of amyloid beta induced neurodegeneration and ovarian cancer metastasis. Reifert has authored several publications investigating topics like tau fragmentation and the mechanism of action of cancer drug Bendamustine. His research skills include tissue culture, molecular techniques, microscopy, and cytotoxicity assays.
This document provides a summary of Jack Ryan Reifert's education, experience, publications, and research skills. Reifert holds a Ph.D. in Molecular, Cellular, and Developmental Biology from UCSB and a B.S. in Pharmacological Chemistry from UCSD. He has postdoctoral research experience at UCSB studying bacterial peptide display for ovarian cancer detection and inhibition. Reifert has over 10 years of experience in neuroscience research and industrial research, and he has authored several publications in peer-reviewed journals.
John Nixon has over 15 years of experience evaluating biological targets for therapeutic monoclonal antibody projects at MedImmune and CAT. He rapidly assesses new target proposals, coordinating expert input to support project initiation. Additionally, he has successfully organized large internal scientific symposia across continents. Nixon also provides strategic input, helping scope key target opportunities in multiple sclerosis and atopic dermatitis. He has strong expertise in small molecule drug discovery from his previous role at Roche.
This document provides a summary of Venkatakrishna Shyamala's background and experience in molecular diagnostics and blood testing spanning over 25 years. It includes information on her educational background, work experience at various biotech companies focusing on assay development and next generation technologies, areas of expertise, selected publications, and extra mural funding. She has consulted for various companies and organizations, and served on committees providing expertise in molecular methods for clinical testing.
Similar to David C Crosby PhD MSL CV 120814 linkedin (20)
1. DAVID C. CROSBY, PH.D. San Francisco, CA 94116
415.823.5456 • david.crosby.msl@gmail.com • LinkedIn
Highly motivated medical science liaison interested in exciting medical communications opportunities in
oncology, infectious disease, immunology, or cardiology. Demonstrated ability to engage healthcare
professionals in high-level scientific communication at international infectious disease conferences.
Experienced with profiling national and regional opinion leaders and with building tools and resources
for growing medical affairs business units. Provided competitive intelligence and distilled medical
information from conferences for internal commercial and clinical functions. Nine years of
communications experience as an infectious disease research scientist at both the University of California,
Irvine and UC San Francisco.
PROFESSIONAL EXPERIENCE
Melinta Therapeutics, New Haven, CT (Contracted via The Medical Affairs Company) 2014 - present
Medical Science Liaison, Infectious Disease Western US Territory
As a founding member of Melinta’s field medical affairs team, I identified, profiled, and engaged skin
and skin structure and gonococcal infection opinion leaders in CA, OR, WA, NV, CO, AZ, NM, and ID in
order to bolster Melinta’s relationships with the healthcare community.
• Engaged KOLs at advisory board meetings in an effort to understand how delafloxacin and
Melinta’s preclinical pipeline can best navigate the complex regulatory, commercial, and clinical
challenges unique to antibiotics.
• Represented Melinta medical affairs at international scientific meetings (ICAAC and IDweek),
engaging both KOLs and the heathcare community at large in detailed scientific discussion about
the potential clinical utility of delafloxacin.
• Worked with Melinta marketing to gather key competitive scientific intelligence both at
conferences and from scientific literature important for the commercialization of delafloxacin and
for future development of preclinical candidates.
• Created KOL profiling tools and medical information slide decks (disease state, drug-specific,
current medical practice guidelines, etc.) to be used as cornerstone resources for Meltina’s
growing medical affairs business unit.
University of California, San Francisco (UCSF)., San Francisco, CA 2011 - 2014
Lead Virologist, HIV Accessory and Regulatory Complexes Center (HARC) for the Mission Bay Campus
Assembled and lead interdisciplinary teams of scientists to tackle major unmet biomedical questions
pertaining to the intersection of human immunology and HIV infection.
Initiated and managed collaborative research stemming from HARC-initiated proteomic surveys.
Authored several publications detailing novel HIV biology in top-tier, peer-reviewed journals.
Presented complex scientific findings to diverse audiences at laboratory meetings and
international research conferences.
Productive collaborations with UCSF investigators including Charly Craik, Ph.D., John Gross,
Ph.D., and Nevan Krogan, Ph.D.
Mentored/trained visiting postdoctoral researchers, graduate students, undergraduate
volunteers, and research technicians.
University of California, San Francisco (UCSF)., San Francisco, CA 2011 - 2014
Postdoctoral Research Scientist, Alan D. Frankel, Ph.D. Laboratory
Designed, executed, and communicated research investigating the mechanisms of retroviral RNA
metabolism within immune cells.
Designed and executed dozens of novel scientific experiments exploring HIV RNA metabolism.
Extensive knowledge and analysis of relevant scientific and clinical literature.
Frequently interpreted and communicated complex scientific information at laboratory meetings
and international research conferences.
2. PROFESSIONAL EXPERIENCE ( CONT I NU ED)
Advanced Genetic Systems, Inc., San Francisco, CA 2011 - 2014
Virology Consultant for AGS Founder and CEO, Robert Nakamura, Ph.D.
Provided key scientific advice to empower detailed virologic studies of putative inhibitors of HIV Rev
and Tat proteins.
Designed and developed assays essential to drug characterization in an infectious context.
Initiated studies and gathered data critical to the success of several SBIR grants.
Communicated key scientific data to medicinal chemist collaborators at UCSF.
University of California, Irvine, Irvine, CA 2005 - 2011
Graduate Student Researcher – HIV Drug Discovery and Development
Discovered and developed compounds targeting HIV integrase potent against drug-resistant HIV.
Presented scientific data at international research conferences.
Extensive training in data and literature critical analysis.
Taught several undergraduate courses as a teaching assistant.
Published several high-quality research articles in peer-reviewed journals.
Genentech, Inc., South San Francisco, CA 2003 - 2005
Senior Analyst, Quality Control Stability
Managed product expiry studies for Genentech’s growth hormone line of products (Protropin, Nutropin,
and Nutropin AQ) under FDA 21 CFR, cGMP regulation.
Managed and performed cGMP-compliant experiments to determine product shelf life.
Validated standard operating procedures (SOPs) determine product photo- and cryo-stability.
Trained junior analysts in assay and analysis SOPs.
Cygnus, Inc., Redwood City, CA 2002 - 2003
Senior Analyst, Quality Control Stability
Managed product expiry studies for the GlucoWatch G2 Biographer under 21 CFR regulation.
Performed cGMP-compliant analyses to determine product shelf life and sterility.
Designed and validated assays to determine product sterility.
Santa Cruz Biotechnology, Inc., Santa Cruz, CA 1999 - 2001
Research Assistant, Peptide Synthesis
Produced and characterized synthetic peptides for use as immunogens for antibody generation.
EDUCATION & AFFILIATIONS
Doctorate of Philosophy (Ph.D.), Experimental Pathology, 2010
University of California, Irvine – Department of Pathology, Irvine, CA
Bachelor of Arts (B.A.) – Molecular, Cellular and Developmental Biology, 2002
University of California, Santa Cruz, CA
Bachelor of Arts (B.A.) – Music, 2002
University of California, Santa Cruz, CA
CONTINUING EDUCATION
UCSF/Burrill & Company-Sponsored “Idea to IPO” Course on Bioentrepreneurship, 2013
UCSF PharmChem 152 “Drug Discovery and Development” Instructed by Brian Shoichet, 2013
UCSF Scientific Leadership & Management Skills: A Course for Postdocs & Junior Faculty, 2013
David C. Crosby, Ph.D. Page 2 of 4
3. PROFESSIONAL AFFILIATIONS
American Society for Microbiology (ASM), 2005-present
American Association for the Advancement of Science (AAAS), 2005-present
OTHER INTERESTS
• President, Delta Omega Chi Fraternity at UC Santa Cruz, 1998-2001
• Founding member of the UCSC Inter Greek Council and the Delta Omega Chi Alumni
Association gaining 501(c)(3) California non-profit status in 2005.
• Landscape photography, piano and electronic music composition
SELECTED PUBLICATIONS
Jayaraman, B., Crosby, D. C., Homer, C., Ribeiro, I., Mavor, D., and A. D. Frankel, RNA-directed
remodeling of the HIV-1 Rev protein orchestrates assembly of the Rev-Rev response element complex, In
Press, eLife, December 2014.
Determined the functional relevance of novel Rev-RNA interactions as observed in the solved
Rev dimer-HIV RNA structure on virus replication and RNA metabolism in infected cells.
Crosby, D. C., Lei, X., Gibbs, C. Reinecke, M. G., and W. E. Robinson, Jr., Mutagenesis of lysines 156 and
159 in human immunodeficiency virus type 1 integrase (IN) reveals differential interactions between
these residues and different IN inhibitors. In press, Natural Product Communications, July 2014.
Designed and characterized the potencies of novel hybrid inhibitors targeting HIV IN against
mutant recombinant IN in biochemical assays and HIV containing mutant IN in virologic assays.
Kim, D. Y.*, Kwon, E.,* Hartley, P. D.,* Crosby, D. C., Mann, S., Krogan, N. J.,* and J. D. Gross* CBFβ
stabilizes HIV Vif to promote APOBEC3 ubiquitination at the expense of RUNX1 mediated gene
expression. Mol. Cell. 2013 Feb 21;49(4) *These authors contributed equally.
Determined the impact of HIV Vif interactions with host cellular CBFβ on virus replication and
host cellular gene expression at RUNX1 loci.
Stanley D. J.*, Bartholomeeusen, K.*, Crosby, D. C., Kim, D. Y., Kwon, E., Yen, L., Cartozo, N. C., Li, N.,
Jäger, S., Mason-Herr, J., Hayashi, F., Yokoyama, S., Krogan, N. J., Harris, R. S., Peterlin B. M., and J. D.
Gross. Inhibition of a NEDD8 cascade restores restriction of HIV by APOBEC3G. PLoS Pathog. 2012
Dec;8(12). *These authors contributed equally.
Determined the impact of host cellular UBE2F, UBE2M, RBX1, and RBX2 depletion on virus
replication in T-cells in tissue culture.
Chow, B.T., Soto, M., Lo, B. L., Crosby, D. C. and D. Camerini. Antibacterial activity of four novel
human beta-defensins: HBD-19, HBD-23, HBD-27, and HBD-29. Polymers 2012, 4(1), 747-758
Designed, expressed, and purified several recombinant human beta-defensin proteins.
Crosby, D. C., Lei, X., Gibbs, C. G., McDougall, B. R., Robinson Jr., W. E., and M. G. Reinecke. Design,
synthesis, and biological evaluation of novel hybrid dicaffeoyltartaric/diketo acid and tetrazole-substituted
L-chicoric acid analog inhibitors of human immunodeficiency virus type 1 integrase. Journal
of Medicinal Chemistry. 2010, 53 (22), pp 8161–8175
Designed and characterized inhibitors targeting HIV IN in biochemical and virologic assays.
David C. Crosby, Ph.D. Page 3 of 4
4. SELECTED PRESENTATIONS
Jayaraman, B., Crosby, D. C., Homer, C., Ribeiro, I., Mavor, D., and A. D. Frankel, Structural biology of a
HIV-1 Rev-RRE complex. Poster presentation at the 2014 NIH Structural Biology Related to HIV/AIDS
Meeting.
Fernandes, J. D., Crosby, D.C, Faust, T. B., Nakamura, R., Strauli, N., Hernandez, R. D., and A. D.
Frankel, The selfish evolution of two overlapping HIV-1 genes. Poster presentation at the 2014 NIH
Structural Biology Related to HIV/AIDS Meeting.
Crosby, D. C., and A. D. Frankel, An exciting year in the HARC virology core. Oral presentation on
September 27th, 2012, UCSF HARC Center Minisymposium
Crosby, D. C., and A. D. Frankel, HIV-1 Rev oligomerization and viral replication. Oral presentation on
October 24th, 2011, UCSF HARC Center Minisymposium
Crosby, D. C., and W. E. Robinson Jr. Mutations in human immunodeficiency virus type 1 integrase
improve upon viral replication and enzyme catalytic defects conferred by a Q148A mutation within
integrase plus enhance resistance to integrase inhibitors. Poster presentation on March 15th, 2010, Palm
Springs Symposium on HIV/AIDS
Crosby, D. C., and W. E. Robinson Jr. Mutations outside the HIV-1 integrase active site enhance
resistance to the diketo acid integrase inhibitor, XLI-161-1, and elvitegravir. Oral presentation on March
14th, 2009, Palm Springs Symposium on HIV/AIDS
Crosby, D. C., and W. E. Robinson Jr. Mapping of a human immunodeficiency virus type 1 integrase
inhibitor binding pocket, Poster presentation on March 15th, 2008, Palm Springs Symposium on
HIV/AIDS
David C. Crosby, Ph.D. Page 4 of 4